Spinogenix’s ALS hopeful to advance to registrational trial
SPG601 calms brain activity in men with fragile X, helping them to focus
Synaptic Regeneration: A New Frontier in Schizophrenia Treatment
Spinogenix Receives Positive FDA Feedback for SPG601 in Fragile X Syndrome
What Inspired You to Pursue a Career in Life Sciences? — Xtalks Open Mic
Restoring Synapses to Fight Neurodegeneration with Spinogenix CEO Dr. Stella Sarraf
SPG601 granted orphan drug status in EU for treating fragile X
Early positive signals of cognitive outcomes in mild to moderate Alzheimer patientstreated with the synaptic regenerative small molecule, SPG302 – AAIC 2025 Poster
First synaptic regenerative therapy for ALS gets orphan status
Regulatory actions for June 4, 2025
